1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hanall Biopharma Co., Ltd.

Hanall Biopharma Co., Ltd.

KKRX:009420
40,200.00
KRW
-100.00
(-0.25%)
-488.98EPS
3.17TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,826.46
2,006.32
1,797.79
1,636.34
1,651.8
1,781.07
2,121.04
1,730.4
1,987.09
2,187.02
2,653.13
2,771.42
3,042.74
3,193.76
Basic EPS, GAAP
-529
-314
-159
40
114
64
375
386
174
5
69
-36
-109
-488.98
Free Cash Flow per Basic Share
-352.95
-176.59
-85.38
-1.6
783.05
-95.29
238.9
-126.17
-159.65
349.68
402.07
-273.43
-322.66
-424.19
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,473.03
1,139.23
1,904.25
2,044.91
2,172.82
2,284.59
2,743.77
3,541.94
3,192.82
3,319.29
3,673.44
3,316.25
3,183.9
3,182.81
Tangible Book Value per Share
957.37
915.19
1,710.27
1,816.54
1,974.27
2,176.64
2,534.34
3,247.33
2,819.89
2,849.01
3,030.18
2,295.67
1,912.24
2,078.19
Basic Weighted Avg Shares
41
40
45
51
51
52
51
51
51
50
51
50
51
51
Sales/Revenue/Turnover
74,228
80,880
80,023
82,882
84,231
91,839
108,452
88,602
101,594
109,995
134,910
138,944
155,185
162,659
Operating Margin (%)
-17.49
1.01
-5.35
0.34
4.2
5.96
15.76
6.7
9.94
1.37
1.64
0.17
-0.59
2.93
Depreciation Expense
1,952
2,260
2,317
2,235
2,162
1,989
2,715
2,894
2,725
3,053
3,247
3,121
3,561
3,358
Net Income, GAAP
-21,499
-12,658
-7,077
2,026
5,813
3,300
19,174
19,764
8,896
251
3,509
-1,805
-5,559
-24,904
Effective Tax Rate (%)
- -
- -
- -
- -
- -
17.42
- -
- -
- -
86.97
- -
- -
- -
- -
Profit Margin (%)
-28.96
-15.65
-8.84
2.44
6.9
3.59
17.68
22.31
8.76
0.23
2.6
-1.3
-3.58
-15.31
Working Capital
28,369
30,108
78,687
82,043
85,584
106,604
106,910
106,295
96,695
83,254
75,925
50,633
40,445
30,722
LT Debt
- -
3,000
- -
- -
- -
- -
201
277
912
751
590
700
15,586
15,497
Total Equity
59,626
45,809
95,216
104,357
111,198
116,918
140,417
181,273
163,492
168,256
186,218
168,351
161,681
161,626
Return on Invested Capital (%)
- -
- -
- -
- -
- -
4
- -
- -
- -
0.12
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
2.89
- -
- -
- -
0.15
- -
- -
- -
- -
Return on Common Equity (%)
-31.09
-24.01
-10.04
2.03
5.39
2.89
14.9
12.29
5.16
0.15
1.98
-1.02
-3.37
-15.68

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
16,331
28,609
29,498
LT Borrowings
15,000
15,000
15,000
LT Finance Leases
586
587
497
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
2,221,662
2,808,181
3,168,725

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
84,913
102,082
92,900
Cash, Cash Equivalents & STI
24,743
36,158
30,196
Accounts Receivable, Net
16,869
15,223
18,842
Inventories
38,112
45,465
40,816
Total Current Liabilities
44,468
63,830
62,178
Payables & Accruals
- -
- -
- -
ST Debt
16,331
28,609
29,498
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.07%
-1.95%
-3.96%
Free Cash Flow
-5,041.1%
-83.98%
20.05%
Net Income, GAAP
169.88%
239.93%
208.01%
Sales/Revenue/Turnover
7.43%
12.05%
11.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34,094
31,593
36,840
36,417
138,944
2025
36,150
40,682
40,804
37,549
155,185
2026
40,031
44,276
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6
-66
4
31.91
-36
2025
-4
12
5.82
-123.07
-109
2026
5.42
-378.27
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Su-Jin Park
Full Time Employees
315
Sector
Health technology
Industry
Pharmaceuticals: major
Address
43, Sangseodang 1-gil Daejeon DE South Korea 04386
IPO Date
Dec 18, 1989
Website
hanall.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hanall Biopharma Co., Ltd. (KRX: 009420.KS) is a global biopharmaceutical company that researches, develops, manufactures, and commercializes innovative specialty drugs, biologics, and generics targeting endocrine, circulatory, urologic, immunology, oncology, neurology, ophthalmology, and other therapeutic areas. Founded in 1973 and headquartered in Seoul, South Korea, with additional facilities in Daejeon and operations in the United States, Japan, and Indonesia, the company offers a portfolio of marketed products including Normix for acute enteritis and hyperammonemia; Biotop-D for intestinal regulation and constipation; Eligard for palliative treatment of prostate cancer; and Alphabon for hypocalcemia, tetany, and osteoporosis associated with vitamin D metabolism disorders; alongside antibiotics, amino acid formulations, and other prescription pharmaceuticals sold in South Korea and internationally. Its research and development pipeline features lead candidates such as batoclimab (HL161), a fully human anti-FcRn monoclonal antibody in Phase 3 and Phase 2 trials for myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves' disease; imeroprubart, an advanced FcRn inhibitor in development for cutaneous lupus erythematosus, Sjögren's disease, difficult-to-treat rheumatoid arthritis, and other autoimmune conditions; tanfanercept (HL036), a TNF-alpha inhibitor protein in Phase 3 studies for dry eye disease; and HL192, a Nurr-1 activator for Parkinson's disease. In recent developments, Hanall Biopharma signed an exclusive global licensing agreement with Turn Biotechnologies in 2024 to develop mRNA-based epigenetic reprogramming therapies for age-related eye and ear conditions, valued at over $300 million for the initial product; announced the termination of its HL161 licensing agreement in 2025; received orphan drug designation for batoclimab in Japan; completed a Phase 1 study of HL192 (ATH-399A) with Daewoong Pharmaceutical and NurrOn Pharmaceuticals showing good tolerability; reported Q3 2024 revenue of 36.8 billion KRW; appointed Almira Chabi as Chief Medical Officer and Christopher W. Slavinsky as Chief Business Officer; and continued advancing multiple Phase 3 trials including VELOS-4 for tanfanercept.